16th Annual Immunogenicity for Biotherapeutics 2015

The 16th Annual Immunogenicity for Biotherapeutics 2015 provides an insight on the uncertainty surrounding immune response prediction and minimization, including strategies to overcome immunogenicity challenges from pre-clinical and development all the way through post-clinical stages.

Key Topics

• The risks of immunogenicity from concept to product - Strategies and case studies
• Technical and regulatory perspectives from senior FDA and industry experts
• Must-have features of molecular design to minimize or eliminate epitopes
• Transgenic animal models to get the best grasp on predicting immunogenicity
• Managing and reducing off-target toxicity concerns with antibody-drug conjugates and other protein therapeutics
• Newly-developed varieties of biomolecules, including biosimilars, nanomedicines, bispecifics and antibody-drug conjugates
• Higher-order structure techniques and assessment to improve the safety of therapeutic candidates

Who should Attend

Attendees from:

• Biologic Research
• Therapeutic Protein
• Immunochemistry
• Immunotherapeutics
• Immunology
• Protein Biochemistry
• Bioanalytical Method Development
• Immunoassays
• Antibody Engineering
• Drug safety
• Pharmacokinetics/ Pharmacodynamics
• Bioanalytical Research
• Assay Development